Skip to main content
SpringerLink
Log in

Voriconazole in the Treatment of Invasive Aspergillosis: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Muijsers RBR, Goa KL, Scott LJ. Voriconazole: in the treatment of invasive aspergillosis. Drugs 2002; 62(18): 2655–64

    Article  PubMed  CAS  Google Scholar 

  2. Rex JH. Voriconazole: a viewpoint by John H. Rex. Drugs 2002; 62(18): 2665

    Article  Google Scholar 

  3. Patterson TF. Voriconazole: a viewpoint by Thomas F. Patterson. Drugs 2002; 62(18): 2665–6

    Article  Google Scholar 

  4. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5(2): 120–35

    Article  PubMed  CAS  Google Scholar 

  5. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999 Jan; 12(1): 40–79

    PubMed  CAS  Google Scholar 

  6. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41(11): 2492–6

    PubMed  CAS  Google Scholar 

  7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408–15

    Article  PubMed  CAS  Google Scholar 

  8. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–71

    Article  PubMed  CAS  Google Scholar 

  9. De Pauw B. Clinical potential and experience of voriconazole [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 7

    Google Scholar 

  10. Pfizer Inc. VFend (voriconazole): annotated package insert (US). 2002; 1–43

  11. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34(5): 563–71

    Article  PubMed  CAS  Google Scholar 

  12. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346(4): 225–34

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Texas Health Science Center at Houston, Houston, Texas, USA

    John H. Rex

  2. The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

    Thomas F. Patterson

Authors
  1. John H. Rex
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas F. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rex, J.H., Patterson, T.F. Voriconazole in the Treatment of Invasive Aspergillosis: profile report. Drugs Ther. Perspect 19, 5–7 (2003). https://doi.org/10.2165/00042310-200319050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319050-00002

Keywords

Search

Navigation